Bowel Diseases, Inflammatory Clinical Trial
Official title:
Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease
This is a multicenter, prospective, randomized, open study comparing two anti-pneumococcal vaccination strategies in patients with Chronic Inflammatory Bowel Disease (CIBD) treated by immunosuppressants and/or biotherapies. At present such patients are poorly protected by anti-pneumococcal vaccination. In addition, vaccination efficacy in this type of patient is much weaker than in the general population. There are two types of anti-pneumococcal vaccines: firstly a polysaccharide, Pneumo23® (PSV-23®) vaccine and secondly a conjugate, Prevenar13® vaccine. New recommendations have just been issued by the HSCP advising immunocompromised patients to follow a vaccination plan combining one dose of Prevenar13® followed by one dose of PSV-23® after an interval of two months. In the case of young children infected with HIV, the recommendation is to multiply doses of Prevenar13® before the PSV-23® injection to improve vaccine efficacy in these immunocompromised patients. Our study aims to identify an optimal vaccination strategy for immunocompromised CIBD patients by combining use of a conjugate vaccine, Prevenar13® and a polysaccharide vaccine, PSV-23®. We will compare the use of one or two doses (M0 +/- M2) of Prevenar13® combined with a later PSV-23® injection (M4) on vaccination immunogenicity measured by antibody titer against at least nine of the thirteen pneumococcal serotypes contained in Prevenar13®. We also want to evaluate the immunological impact of these different strategies in their capacity to stimulate a memory B anti-pneumococcal response more effectively. With this aim, we are studying all immunological functional aspects of the antibodies and B lymphocytes induced by the two vaccine strategies.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00640809 -
Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole
|
Phase 4 | |
| Completed |
NCT04587713 -
Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT05043363 -
LuCID - Investigating the Use of a Novel Digital Rectoscope for Community Examinations During COVID-19
|
||
| Completed |
NCT02799615 -
Anti-TNF Therapy for Refractory Colitis in Hospitalized Children
|
||
| Completed |
NCT03408470 -
TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT02760940 -
Anemia in Inflammatory Bowel Disease
|
Phase 4 | |
| Terminated |
NCT04032756 -
Tofacitinib Registry of Patients With Ulcerative Colitis in Germany
|
||
| Completed |
NCT03999294 -
Bmgim Music Therapy Method in Reducing Stress in Patients With Inflammatory Bowel Disease
|
N/A |